Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Sickle cell therapy drought ends
source: JAMA
year: 2017
authors: Voelker R
summary/abstract:After nearly 20 years without new treatments for sickle cell disease, the FDA has approved L-glutamine oral powder to reduce severe complications of the blood disorder in patients aged 5 years or older. It also is the first sickle cell disease treatment approved for pediatric patients.
Marketed as Endari, L-glutamine is an amino acid that can help prevent sickle red blood cells from sticking to the endothelial cells of blood vessels, which causes vaso-occlusion that results in severe pain and organ damage. Previously, the antimetabolite hydroxyurea had been the only FDA-approved drug for sickle cell disease.
DOI: 10.1001/jama.2017.10152read more full text
+myBinderRelated Content
-
Discovery First in Human: Bringing Awareness of Sickle Cell Diseasehttps://www.youtube.com/watch?v=kffu_YvJ...
-
SUSTAIN Clinical Trial Results Show Crizanlizumab Reduced Sickle Cell–Related Pain CrisesResults from the Phase 2 SUSTAIN clinica...
-
Methadone provides pain relief for kids with sickle cellMany children with sickle cell disease e...
-
Magnesium for treating sickle cell diseaseBACKGROUND: Sickle cell disease is an a...
-
T-Boz: How Sickle Cell Impacts Her Careerhttps://www.youtube.com/watch?v=XpczDlN3...
-
Immunoglobulin G Responses Against Falciparum Malaria Specific Antigens are Higher in Children with Homozygous Sickl...Background: High Immunoglobulin G (IgG)...
-
Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients Wi...Sancilio Pharmaceuticals Company, Inc. (...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.